News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Athersys, Inc. Reports on Progress in Phase 2 Study of MultiStem for Ischemic Stroke


10/2/2012 9:52:13 AM

CLEVELAND, Oct. 2, 2012 (GLOBE NEWSWIRE) -- Athersys, Inc. (Nasdaq:ATHX) recently completed enrollment of the first patient cohorts of its Phase 2 study of MultiStem®, a novel adult stem cell therapy being developed by Athersys, administered to patients within approximately 1 to 2 days after they have experienced an ischemic stroke. The independent safety committee reviewed data from these patients, finding that both of the doses evaluated were safe and well tolerated, and therefore, recommended proceeding with high dose administration to patients for the remainder of the trial.

Read at GlobeNewswire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES